Menu
← Oncology Approval Tracker
FDA DECISION ·
Posfrea
palonosetron · Avyxa Holdings
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For children from age 1 month to under age 17 to prevent acute nausea and vomiting associated with initial or repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The approval extends this palonosetron injection’s antiemetic indication to young children receiving cancer chemotherapy.
What research teams should watch
Use age- and weight-specific orders and administer at the appropriate time before the chemotherapy regimen.
PRIMARY RECORDS